OBJECTIVE: Our goal was to establish whether psychosocial risk factors for nonadherence, previously identified as negative predictors of warfarin prescribing, are predictors of adverse events for patients with nonvalvular atrial fibrillation receiving warfarin.
P atients with nonvalvular atrial fibrillation have a fivefold increase in the incidence of thromboembolic stroke. 1, 2 Several factors have been identified that increase the risk of an embolic event in patients with nonvalvular atrial fibrillation including increasing age, prior transient ischemic event or stroke, hypertension, diabetes, and left ventricular dysfunction. 2, 3 While anticoagulation with warfarin has been shown to reduce the incidence of embolic events, [3] [4] [5] [6] [7] there is an increased risk of bleeding. A number of clinical risk factors for bleeding while receiving anticoagulation have been identified, such as an international normalized ratio (INR) greater than 3, poorly controlled hypertension, history of gastrointestinal bleeding, and increasing age, [8] [9] [10] [11] [12] [13] [14] but no published models have included psychosocial risk factors in addition to the known clinical risk factors. Several clinical reasons for an elevated INR have been identified including drug-drug interactions, noncompliance with drug or diet, worsened heart failure, and impaired liver function. 15, 16 Current alcohol abuse has been shown to be associated with major bleeding and an elevated INR in several small studies 14, 17 and in 1 large study 18 while others have not
shown such an association. 16, 19 No studies have examined the effect of psychiatric illness on bleeding risk. Despite the evidence supporting the benefits of anticoagulating patients with nonvalvular atrial fibrillation, only 30% to 55% of patients without contraindications are currently receiving warfarin. [20] [21] [22] One of the potential barriers to prescribing warfarin may be physician concern about psychosocial factors that may impair effectiveness and present barriers to therapy. A recent study of Ohio Medicaid patients identified several psychosocial factors that were negative predictors of warfarin use in newly diagnosed cases of atrial fibrillation. 23 Johnston and colleagues demonstrated in this study that patients with substance abuse had an adjusted odds ratio of 0.59 (95% confidence interval (CI) 0.35, 0.99) for receiving warfarin at the time of diagnosis. Patients with other perceived barriers to compliance, including psychiatric illness and social risk factors, had an adjusted odds ratio of 0.84 (95% CI 0.73, 0.97) for receiving warfarin. The social risk factors included no caregiver for the patient, homelessness and previous documentation of noncompliance. In this study psychiatric illness was defined as schizophrenia, affective psychosis (including major depressive disorder, manic disorder, or bipolar affective disorder), paranoia or other nonorganic psychosis as determined by International Classification of Diseases, Ninth Revision, Clinical Modification codes (ICD-9-CM) as these were considered to be likely predictors of nonadherence. No other psychiatric diagnoses were considered. It has yet to be determined whether these negative predictors of warfarin prescribing are risk factors for adverse outcomes in patients receiving warfarin.
The specific aim of this study is to identify and quantify the psychosocial risk factors leading to thromboembolic and hemorrhagic complications in Ohio Medicaid patients who received warfarin for nonvalvular atrial fibrillation. We hypothesize that substance abuse, psychiatric disease, and the social factors that are perceived barriers to adherence increase the risk of both thromboembolic and hemorrhagic events in these patients.
SUBJECTS AND METHODS

Basic Design and Data Source
We performed a retrospective cohort analysis of Ohio Medicaid patients from January 1, 1997, through May 31, 2002 . Data were collected from the Ohio Medicaid administrative claims database which has been well described elsewhere. [23] [24] [25] Briefly, the database includes fee-for-service data from all institutions, providers, and pharmacies that provide services to Ohio Medicaid enrollees. The 2 Ohio Medicaid categories are people who are Aged, Blind, or Disabled and Covered Families and Children (CFC). All enrollees must meet income eligibility requirements: elderly or disabled recipients must earn no more than 64% of the federal poverty level. Recipient identification numbers link the data. The Institutional Review Board at the University of Cincinnati approved the use of this database.
Patient Selection
We identified all subjects with 2 or more claims containing an ICD-9-CM for atrial fibrillation (427.31) during the study period of January 1, 1997, through May 31, 2002 . Two claims were required for inclusion to ensure that we did not include subjects with transient atrial fibrillation. Exclusion criteria are described in Figure 1 . We used pharmacy claims data to determine when patients filled prescriptions for warfarin, and we examined all warfarin prescriptions filled. Searching for National Drug Codes corresponding to warfarin and the ICD-9-CM codes indicating warfarin use identified warfarin prescriptions for these patients. Patients were included in the study only if they filled 2 or more prescriptions for warfarin and if the average time between prescription refills was less than 100 days. We chose the 100-day window because some patients, on a stable dose of anticoagulation, may receive up to a 3-month supply per refill.
Risk Factors
We identified the psychosocial features of interest from the database using ICD-9-CM codes and then categorized them as being present or absent for each patient. Psychiatric illness was defined as schizophrenia (ICD-9-CM code 295.x), affective psychosis (296.x), paranoia (297.x), or other nonorganic psychosis (298.x). Affective psychosis includes major depressive disorder, manic disorder, and bipolar affective disorder. Substance abuse was defined as alcohol dependence (303.x), drug dependence (304.x), or nondependent abuse (305.x excluding 305.1-tobacco use disorder). Social risk factors included lack of housing (V60.0), inadequate housing (V60.1), inadequate material resources (V60.2), persons living alone (V60.3), no other household member able to render care (V60.4), or noncompliance with medical treatment (V15.81).
Covariates, which, a priori, were believed to confer independent risks for the outcomes, were identified from the dataset using ICD-9 CM codes. Hypertension (401-405), diabetes mellitus (250.x), chronic heart failure (402.x1, 404.x1, 404.x3, 428), liver disease (070.2-6, 070.9, 570, 571.x, 572.2-4, 572.8), and renal disease (584.x, 585.x, 586.x) were the potential confounders identified for each patient as being present or absent. We also included a history of deep vein thrombosis (451.1) in the modeling process as another indication for warfarin therapy. Demographic data were used to obtain the age, sex, and race for each subject. Another potential covariate included in the analysis was frequency of warfarin refills, thought to be a crude measure of adherence. This proxy for
Excluded Patients
Patients with at least one ICD-9-CM code for atrial fibrillation: 38,508 2 or more codes for atrial fibrillation: 25, 200 No valvular heart disease: 23,346
At least one warfarin prescription: 11,395
2 or more warfarin prescriptions averaging less than 100 days apart:
9,885
Patients included in the analysis: 9,345
Only one code for atrial fibrillation: 13,308 adherence was considered present if the average time between prescription refills for a subject was greater than 32 days (the median prescription refill time) and absent if less than or equal to 32 days.
Outcomes
We defined adverse events based on ICD-9-CM codes that were recorded on inpatient hospitalization claims. Inpatient hospitalization codes were required to improve the reliability of the claim and the diagnosis. The primary adverse events considered were stroke (434. 
Time at Risk
The date of a patient's initial warfarin prescription claim was used to define the start of the patient's at-risk period. A patient was then considered to be at risk until an adverse event occurred. Patients without adverse outcomes were censored at 30 days following their last prescription for warfarin, their date of disenrollment from Medicaid or on their date of death. A 30-day window was chosen to allow patients to finish taking their last prescription refill.
Analysis
We used descriptive statistics including the t-test and the w 2 -test to characterize the study sample, stratified by risk factor. Event rates for each outcome (stroke, intracranial hemorrhage, and gastrointestinal bleeding) were calculated for each risk factor group and for the cohort as a whole.
Cox proportional hazards models were used to evaluate the univariate relationship between each risk group and the potential confounders with each outcome. We then selected the variables that were significant predictors at Po.05 to be included in the multivariable models. Because of the large sample size and the large number of outcomes, each adjusted model included all of the significant covariates in order to maintain the face validity of the results. SAS version 8.2 (Cary, NC) was used for all analyses.
RESULTS
Patient Characteristics
25,200 patients were identified as having 2 or more ICD-9-CM codes for atrial fibrillation. After the inclusion and exclusion criteria were applied, 9,345 patients remained in the analysis. These patients were followed for a mean of 740 days and filled an average of 25 warfarin prescriptions during this time.
The mean age (SD) of the study sample was 72 (13.8) years (Table 1) . A significant majority of patients were women and were white. In general, the sample had numerous comorbid conditions, particularly hypertension and chronic heart failure. The subjects with substance abuse tended to be younger and male, and were more likely to be African American. They were also more likely to have liver disease and hy- Age k pertension than the other subgroups. The subjects with social risk factors for nonadherence tended to be older and were more likely to have chronic heart failure, diabetes mellitus, and renal disease (Table 1) . With regard to the average time between prescription refills (Table 1) , subjects with substance abuse and with social risk factors averaged significantly more time between prescription refills than subjects without risk factors for nonadherence. However, subjects with psychiatric illness filled prescriptions more frequently than any other risk group examined.
The percentage of subjects with each outcome and the baseline event rates are presented for each risk group in Table 2 . Significantly more strokes occurred in the subjects with psychiatric illness and in the subjects with social risk factors for nonadherence. Significantly more intracranial hemorrhages occurred in subjects with substance abuse and psychiatric illness. All 3 risk groups had significantly more gastrointestinal bleeding events than the group with no risk factors.
Risk Ratios
In the univariate analysis (Table 3) , there were several significant predictors of increased risk for stroke at the Po.05 level including psychiatric illness, social risk factors for nonadherence, hypertension, diabetes mellitus, renal disease, and African-American race. Only 2 variables conferred an increase risk of intracranial hemorrhage at the Po.05 level: substance abuse, and psychiatric illness. Multiple variables significantly increased the risk of gastrointestinal bleeding at the Po.05 level: substance abuse, psychiatric illness, social risk factors, chronic heart failure, diabetes mellitus, liver disease, renal disease, and refill time less than or equal to 32 days.
In the final adjusted Cox proportional hazards model ( Table 3 ) for stroke that included all the variables significant at the Po.05 level in the univariate models, only psychiatric illness, diabetes mellitus, and African-American race were significant predictors of increased risk for stroke. The final model for intracranial hemorrhage included both psychiatric illness and substance abuse as significantly increasing the risk. In the adjusted model for gastrointestinal bleeding, the risk was significantly increased by substance abuse, psychiatric illness, social risk factors for nonadherence, chronic heart failure, liver disease, and renal disease. Averaging greater than 32 days between prescription refills was associated with a significantly lower risk of gastrointestinal bleeding.
As there was some overlap between the risk groups studied, we also calculated risk ratios based upon the total number of psychosocial risk factors for each patient. Overall, 53% of the patients had none of the risk factors, 38% had 1 risk factor, Ã Adjusted models only include the variables significant at a Po.05 value in the unadjusted models.
NA, not applicable.
8% had 2 risk factors, and 0.5% of the patients had all 3. For the outcome of gastrointestinal bleeding in the adjusted models, the risk ratio for having any 1 of the psychosocial risk factors was 1.19 (95% CI 1.02, 1.37), for having any 2 risk factors the risk ratio was 1.57 (95% CI 1.26, 1.95), and for a patient having all 3 risk factors the risk ratio was 2.85 (95% CI 1.56, 5.21). This trend was significant with a P value less than .001. For the outcomes of stroke and intracranial hemorrhage the trends towards increasing risk with increasing number of risk factors were significant with P values of .02 for both, however, the individual risk ratios were not all significant.
DISCUSSION
We have shown in the Ohio Medicaid population that psychosocial risk factors for nonadherence, previously identified as negative predictors of warfarin prescribing, are strong predictors of adverse events in patients with nonvalvular atrial fibrillation receiving warfarin compared with patients without these risk factors. Subjects with psychiatric illnesses had a 36% increase in the risk of stroke, a 46% increase in the risk of intracranial hemorrhage, and a 19% increase in the risk of gastrointestinal bleeding. Substance abusers had a 135% increase in the risk of intracranial hemorrhage and a 41% increase in the risk of gastrointestinal bleeding. Subjects with social risk factors for nonadherence had a 28% increased risk for gastrointestinal bleeding. Previous studies have identified clinical predictors for bleeding in patients receiving warfarin. 8, 9, 13 and risk factors for embolic events from atrial fibrillation. 2, 3 Several of these previously identified predictors of adverse events were not significant in our multivariable models but were significant in the univariate analyses. We can only speculate as to why some of the other known risk factors for stroke were not predictive in this analysis. Wang et al. 26 have described prior stroke or TIA, diabetes, and hypertension as predictors of stroke. In our cohort we have excluded patients with a prior stroke or TIA in order to increase the validity of our outcomes (so that they will not be incorrectly coded as ''prior stroke or TIA''). Our cohort has a fairly high proportion of comorbid conditions and it is likely we no longer have the same discriminatory power for some of the other predictors including hypertension. Our incidence rates for the outcomes of stroke, intracranial hemorrhage, and gastrointestinal bleeding are similar to what others have reported in the literature for patients receiving anticoagulation for atrial fibrillation. 14, 27, 28 McMahan et al., 14 demonstrated that alcohol abuse was associated with a 2.7-fold increased risk of major bleeding in a study of 579 veterans, and White et al. 18 demonstrated that an admission for an alcohol-related diagnosis was associated with a 2.6-fold increased risk of major bleeding in a study of over 21,000 patients. Our results are similar to these findings, particularly for intracranial hemorrhage, where we have shown patients have 2.5 times the risk for intracranial hemorrhage if they are substance abusers, which includes drug abuse in addition to alcohol. To our knowledge, there are no previously reported studies examining the effect of psychiatric illness or the social risk factors we identified on adverse events. The validity of using the Ohio Medicaid administrative database for the diagnosis of atrial fibrillation and the use of warfarin has not been directly established. However, Borzecki et al. 29 Our study has several limitations. Prior studies of atrial fibrillation have generally included fewer women and individuals of higher socioeconomic status than in the current study. However, the results of this study are probably applicable to other Medicaid populations. We are aware of no studies that examine the validity of warfarin prescriptions in administrative data. As mentioned above, while administrative billing data has reasonable reliability, chart review would enhance the accuracy of diagnoses and of warfarin use. There is likely a severity of illness bias in using ICD-9-CM codes for diagnosing the psychosocial risk factors limiting the generalizability to only those patients with diagnosed conditions. The results are not adjusted for patient compliance with warfarin use nor for the intensity of anticoagulation therapy because of lack of laboratory results. If a patient had prior events or conditions not documented during the study years, our results would not reflect this information or be adjusted accordingly. However, given the large cohort size and length of follow-up, this information is likely to have minimal effects on our conclusions.
While this study cannot address the question of whether or not patients with these risk factors should be anticoagulated, these patients have an increased risk of adverse events and if they are anticoagulated they should be monitored closely to ensure that INRs remain within the therapeutic range. Furthermore, as patients with psychiatric illness were at an increased risk of both thromboembolic and hemorrhagic complications, it is reasonable to suspect that their level of anticoagulation may alternate between subtherapeutic and supratherapeutic ranges. Another possibility is that these patients are placed at an increased risk of drug interactions with warfarin because of additional antipsychotic medications leading to fluctuations in the INR although this study does not address this. Clearly, further evaluation needs to be performed in order to determine whether these patients benefit from anticoagulation or are only placed at increased risk of adverse outcomes.
In conclusion, our study of Ohio Medicaid patients with nonvalvular atrial fibrillation receiving warfarin demonstrates that psychosocial factors that were previously identified as
